Marimed (MRMD) Cost of Revenue (2011 - 2026)

Marimed (MRMD) has 16 years of Cost of Revenue data on file, last reported at $24.2 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $24.2 million, up 6.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $103.3 million (up 7.13% YoY), and the FY2025 annual result was $101.9 million, up 7.2% from the prior year.
• Cost of Revenue eased to $24.2 million in Q1 2026 per MRMD's latest filing, from $31.1 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $31.1 million in Q4 2025 and troughed at $14.3 million in Q1 2022.
• A 5-year average of $22.0 million and a median of $22.0 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue surged 36.6% in 2022, then advanced 0.21% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $20.0 million in 2022, then grew by 7.81% to $21.6 million in 2023, then climbed by 21.83% to $26.3 million in 2024, then gained by 18.46% to $31.1 million in 2025, then dropped by 22.29% to $24.2 million in 2026.
• Business Quant data shows MRMD's Cost of Revenue at $24.2 million in Q1 2026, $31.1 million in Q4 2025, and $24.4 million in Q3 2025.